Barrett's esophagus future or investigational therapies
Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.
Overview
Overview
- Biomarkers
- Can not be used to confirm the diagnosis of Barrett´s esophagus.
- Can not be used to predict risk of progression.
- Promising for the future[1].
- Endoscopic Therapy
- In patients with confirmed high-grade dysplasia with Barrett’ esophagus, it is more recommended to proceed with endoscopic eradication therapy with radiofrequency ablation (RFA), photodynamic therapy (PDT), or endoscopic mucosal resection (EMR) rather than surveillance.
- In patients who have dysplasia in Barrett’s esophagus associated with a visible mucosal irregularity it is recommended to proceed with endoscopic mucosal resection (EMR) to determine the T stage of the neoplasia[1].
References
References
- ↑ 1.0 1.1 Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). “American Gastroenterological Association medical position statement on the management of Barrett’s esophagus”. Gastroenterology. 140 (3): 1084–91. doi:10.1053/j.gastro.2011.01.030. PMID 21376940. Unknown parameter
|month=ignored (help)
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH